|
ZXDB expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62525548574877E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62725388719309E-12 |
| Normal-vs-Stage2 |
6.64435173547417E-12 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
<1E-12 |
| Stage1-vs-Stage2 |
6.365000E-01 |
| Stage1-vs-Stage3 |
6.861800E-02 |
| Stage1-vs-Stage4 |
5.844100E-02 |
| Stage2-vs-Stage3 |
1.019630E-01 |
| Stage2-vs-Stage4 |
6.505800E-02 |
| Stage3-vs-Stage4 |
6.415400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62492241884138E-12 |
| Normal-vs-AfricanAmerican |
1.43429999988065E-07 |
| Normal-vs-Asian |
1.63336011382853E-12 |
| Caucasian-vs-AfricanAmerican |
2.410200E-01 |
| Caucasian-vs-Asian |
9.527200E-01 |
| AfricanAmerican-vs-Asian |
3.034400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62458935193399E-12 |
| Normal-vs-Female |
1.22124532708767E-15 |
| Male-vs-Female |
3.114400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.44089209850063E-15 |
| Normal-vs-Age(41-60Yrs) |
1.62470037423645E-12 |
| Normal-vs-Age(61-80Yrs) |
3.33066907387547E-16 |
| Normal-vs-Age(81-100Yrs) |
1.410700E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.324000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.860200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.406000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.371800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.606400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.462400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.240800E-03 |
| Classical-VS-Follicular |
6.206600E-01 |
| Classical-VS-Other |
2.899400E-01 |
| Classical-VS-Normal |
3.77475828372553E-14 |
| Tall-VS-Follicular |
3.319800E-02 |
| Tall-VS-Other |
8.611800E-01 |
| Tall-VS-Normal |
1.62458935193399E-12 |
| Follicular-VS-Other |
4.367400E-01 |
| Follicular-VS-Normal |
1.62470037423645E-12 |
| Other-VS-Normal |
4.23660000000714E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.55111512312578E-16 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
4.747800E-02 |
|
|
